News Releases

Keyword Search

May-04-2023
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Apr-27-2023
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
Apr-13-2023
Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors
Apr-03-2023
Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025
Mar-27-2023
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mar-09-2023
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
Mar-02-2023
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
Mar-01-2023
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Feb-01-2023
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Jan-04-2023
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors